Data from FDA’s Mini Sentinel program was among the key data used in the agency’s decision not to change its recommendations for use of Pradaxa (dabigatran) following reports of severe bleeding events.
The agency said in a Nov. 2 drug safety communication that results from a Mini Sentinel assessment indicated bleeding rates...